Navigation Links
Protease inhibitors reach beyond HIV

The immunodeficiency that arises in HIV may be due to excessive programmed cell death of immune CD4 T cells. HIV protease inhibitors (PI) can block programmed cell death in virus-infected T cells in vitro, but have also been shown to induce programmed cell death at higher concentrations. The mechanisms for these paradoxical data are unclear, as is whether PI therapy would aid CD4 T cell reconstitution in HIV patients in vivo.

In a study appearing online on June 2 in advance of the print publication of the July 1 print issue of the Journal of Clinical Investigation, Andrew Badley and colleagues from Mayo Clinic examine whether PIs can inhibit programmed cell death in vivo and the mechanisms involved. The authors show that HIV PIs block programmed cell death induced by three relevant, virus-independent mouse models ?mice with experimental hepatitis, Staphylococcal-induced shock, and experimental stroke.

In each model, HIV PIs block programmed cell death and improve histology, survival, and function. The PIs prevent programmed cell death by maintaining mitochondrial integrity. These data show that PIs block programmed cell death in vivo and that related compounds may be useful for non-HIV disorders also characterized by excessive programmed cell death.


'"/>

Source:JCI


Page: 1

Related biology news :

1. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
2. Anthrax inhibitors identified by Burnham team
3. Enzyme inhibitors block replication of SARS virus
4. Sweet water taste paradoxically predicts sweet taste inhibitors
5. COX-2 inhibitors significantly reduce risk of cancer
6. Public collections of DNA and RNA sequence reach 100 gigabases
7. Natural vitamin E tocotrienol reaches blood at protective levels
8. NC State researchers redesign life for Mars and beyond
9. New classification of eukaryotes has implications for AIDS treatment, agriculture and beyond
10. Avian influenza virus in mammals spreads beyond the site of infection to other organ systems
11. Therapeutic prospects beyond Vioxx
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Protease inhibitors reach beyond HIV

(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... adequate amount of the mineral phosphate can turn a common ... in the April 14, 2009, issue of the Proceedings ... lead to new drugs that would disarm the increasingly antibiotic-resistant ... aeruginosa is one of the most serious hospital-acquired pathogens. ...
... identified a gene that controls the rapid production and ... cell types -- a discovery that could eventually open ... other blood cancers, in which blood cells proliferate out ... of this gene, the scientists uncovered evidence that could ...
... to President Obama, more than 200 organizations, representing the ... President for his outstanding leadership in advancing scientific research, ... below. Dear Mr. President: On ... communities, we wish to commend you and your Administration ...
Cached Biology News:Research could lead to new non-antibiotic drugs to counter hospital infections 2Research could lead to new non-antibiotic drugs to counter hospital infections 3Scientists identify key gene that protects against leukemia 2Scientists identify key gene that protects against leukemia 3Business, scientific, higher education groups laud President Obama's commitment to science 2
(Date:4/27/2015)... VANCOUVER , April 27, 2015 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the year ... are expressed in Canadian dollars and presented under ... year,s phase two DME results did not provide ... but extremely undervalued assets remain at iCo Therapeutics", ...
(Date:4/27/2015)... April 27, 2015  Edico Genome today announced ... from Harvard and Stanford Universities showed the DRAGEN™ ... sequence with 300x depth of coverage by tenfold, ... 60 hours with standard software. "Processing ... especially for individual research and clinical labs, in ...
(Date:4/27/2015)... 2015 Editor Note: ... to bottom . Investor-Edge has initiated ... (NASDAQ: LXRX ), Idera Pharmaceuticals Inc. (NASDAQ: ... SNTA ), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ... Free research report on Lexicon Pharma can be ...
(Date:4/27/2015)... Mass., April 27, 2015  Haemonetics Corporation (NYSE: ... fourth quarter fiscal 2015 of $226.5 million, down ... in the quarter. The Company reported a fourth ... $0.06 per share.  Adjusted net income, exclusive of ... was $24.5 million, up 1%, and adjusted earnings ...
Breaking Biology Technology:iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27
... Terumo Americas Holding, Inc., a U.S. subsidiary of Japan,s ... manufacturers with $3.4 billion in sales and operations in ... entered into a Stock Purchase Agreement to acquire all ... company working to commercialize the world,s first point-of-care technology ...
... make it possible to improve photoelectrochemical cells. In the ... into energy, these cells use sunlight to drive chemical ... involves using a light-sensitive semi-conducting material such as cuprous ... reaction. Although it is not expensive, the oxide is ...
... 2011 Biocept, Inc., a privately-held laboratory testing ... of circulating tumor cells (CTCs) in cancer patients, ... the identification of different CTC phenotypes using its ... paper, appearing in the Journal of Oncology ...
Cached Biology Technology:Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy 2Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy 3Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy 4Harnessing the energy of the Sun: New technique improves artificial photosynthesis 2Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients 2Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients 3
... flexible and easy to use ... control all members of the ... features a clear and easy-to-follow ... setup, user-friendly and highly sophisticated ...
Strip Removal Tool 25/Box...
The bench-top stand comfortably holds up to 6 Finnpipette Digital single- and multichannel pipettes. The crossbars are made of a grippy material to keep the pipettes firmly in place. Individual shelf...
... Analysis Note: Protein determined by Biuret Physical ... mM Tris-HCl, pH 7.6, 1 mM MgCl ... Preparation Unit Definition: One unit will ... minute at pH 9.8 at 37 C. ...
Biology Products: